Charm Therapeutics
charmtx.com
Actively hiring
Pharmaceuticals
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
Overview
Charm Therapeutics applies deep learning protein folding to drug design. Its DragonFold technology models three dimensional protein and ligand structures. The company develops its own oncology programmes.
News
CHARM Therapeutics announces formation of Clinical Advisory Board to support advancement of CHM-029, its next-generation menin inhibitor
PRESS RELEASECHARM Therapeutics announces formation of Clinical Advisory Board to support advancement of CHM-029, its next-generation menin inhibi...
Read more
Report
CHARM Therapeutics announces formation of Clinical Advisory Board to support advancement of CHM-029, its next-generation menin inhibitor
LONDON - 18 August 2026 - CHARM Therapeutics ("CHARM", "The Company"), a biotechnology company addressing resistance in acute myeloid leukemia (AML) with a best-in-class menin inhibitor, announces the formation of its Clinical Advisory Board to support th
Read more
Report
CHARM Therapeutics advances CHM-029, a next-generation menin inhibitor designed to overcome resistance mutations, as its first clinical candidate for acute myeloid leukaemia (AML)
AI-discovered candidate CHM-029 demonstrates robust, dose-dependent tumor regression in pre-clinical AML models and retains potency against all known resistance mutations First-in-human trials expected to begin in Q2 2026 LONDON - 13 November 2025 - CHARM
Read more
Report
Pro access
Upgrade to see all 14 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
London
United Kingdom
HQ